INS and diabetes mellitus: The effectiveness of this approach has been demonstrated by the FDA-approved diabetes therapeutics, insulin detemir, insulin degludec and liraglutide, which are fatty acid-modified peptides that have increased affinity for albumin, and consequently prolonged circulation half-life, compared to their unmodified counterparts62.